Results 61 to 70 of about 162,494 (358)

Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]

, 2019
IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C, Berkowitz, Scott D, Breithardt, Guenter, Fox, Keith AA, Hacke, Werner, Halperin, Jonathan L, Hankey, Graeme J, Hellkamp, Anne S, Mahaffey, Kenneth W, Nessel, Christopher C, Patel, Manesh R, Piccini, Jonathan P, Rodriguez, Fatima, Singer, Daniel E, Ungar, Leo   +14 more
core   +1 more source

The clinical effectiveness and cost-effectiveness of point-of-care tests (CoaguChek system, INRatio2 PT/INR monitor and ProTime Microcoagulation system) for the self-monitoring of the coagulation status of people receiving long-term vitamin K antagonist therapy, compared with standard UK practice : systematic review and economic evaluation [PDF]

, 2015
Funding The National Institute for Health Research Health Technology Assessment programme.Peer reviewedPublisher ...
, , , , , , , , , , , , , , , , , , , , Ahmad, Ansell, Ascione, Azarnoush, Bauman, Bauman, Bauman, Bayer, Bereznicki, Bloomfield, Braun, Briggs, Bronnum-Hansen, Brown, Cayley, Christensen, Christensen, Christensen, Christensen, Christensen, Christensen, Connock, Connolly, Cromheecke, Curtis, Dauphin, DeWilde, Dorman, Drummond, Dunning, Edwards, Eitz, Fitzmaurice, Fitzmaurice, Fitzmaurice, Friberg, Friberg, Fuster, Gadisseur, Gadisseur, Gailly, Gallagher, Garcia-Alamino, Gardiner, Gardiner, Go, Hallan, Havrda, Hemkens, Heneghan, Heneghan, Hentrich, Higgins, Hobbs, Horstkotte, Horstkotte, Horstkotte, Hylek, Jackson, Jones, Jones, Jowett, Kannel, Khan, Kind, Kitchen, Koertke, Koertke, Koertke, Kvidal, Körtke, Körtke, Lafata, Lee, Marini, Matchar, Matchar, Matchar, McCahon, Menéndez-Jándula, Moher, Moon, Muller, Murray, Paioni, Pollack, Rasmussen, Regier, Robinson, Rose, Ruel, Ryan, Ryan, Ryan, Saka, Sawicki, Sawicki, Schmidt, Sidhu, Siebenhofer, Siebenhofer, Slot, Sobieraj-Teague, Sola-Morales, Soliman Hamad, Spackman, Sudlow, Sullivan, Sundberg, Sunderji, Sunderji, Taborski, Tamayo, Vahanian, van, Verret, Visnansky, Voller, Völler, Wallentin, Wallentin, Wang, Wardlaw, Wells, Williams, You   +145 more
core   +1 more source

Micellar Liquid Chromatography Determination of Edoxaban in Oral Solid Dosage Forms: Theoretical Aspects and Validation

ChemMedChem, EarlyView.
A method is developed and validated to quantify edoxaban in solid oral dosage forms using micellar liquid chromatography. A chemometric strategy is used to study the retention mechanism. The procedure is green, economic, safe, and easy to handle; offers high sample throughput; and is reliable, thus useful for pharmaceutical quality control.
Juan Peris‐Vicente, Devasish Bose, Rajendra‐Pasad Pawar, Abhilasha Durgbanshi, Samuel Carda‐Broch   +4 more
wiley   +1 more source

Cancer patients’ experiences of living with venous thromboembolism: A systematic review and qualitative thematic synthesis [PDF]

, 2018
Background: Cancer-Associated thrombosis is common. Recommended treatment is daily injected low-molecular-weight heparin for 6months. Most studies focus on prophylaxis and treatment; few have explored patients’ experience.
Benelhaj, Naima B., Hutchinson, Ann, Ilyas, Muhammad Waqas, Johnson, Miriam J., Maraveyas, Anthony M., Seymour, Julie D.   +5 more
core   +1 more source

Insights Into Patient‐Level Exposure to Actionable Pharmacogenomic Medications in Australia Using a New National Pharmacogenomic Guideline

Clinical Pharmacology &Therapeutics, EarlyView.
This study assessed the use of 35 pharmacogenomic (PGx) medications listed in the Royal College of Pathologists of Australasia (RCPA) guideline, estimated the potential costs of subsidizing PGx testing in Australia, and predicted related prescribing changes.
Bella D. Ianni, Chin Hang Yiu, Mohammad A. Ali, Christine Y. Lu   +3 more
wiley   +1 more source

Clinical Application of Pharmacogenetic-Based Warfarin-Dosing Algorithm in Patients of Han Nationality after Rheumatic Valve Replacement: A Randomized and Controlled Trial

International Journal of Medical Sciences, 2012
Background The polymorphisms of VKORC1 and CYP2C9 play increasingly important roles in the inter-individual variability in warfarin dose. This study aimed to evaluate the feasibility of clinical application of pharmacogenetic-based warfarin-dosing ...
MingSong Wang, XiLong Lang, ShiTao Cui, Ke Fei, LiangJian Zou, Jia Cao, LiangXu Wang, ShengHui Zhang, XinTian Wu, YiLing Wang, Qiang Ji
doaj  

Current strategies of anticoagulation therapy for patients with non-valvular atrial fibrillation

Journal of Arrhythmia, 2012
Cardioembolic stroke accounts for 20–30% of acute brain infarctions in Japan. This condition is often severe and has poor outcomes. Non-valvular atrial fibrillation (NVAF) is the most common cardiac source of emboli in cardioembolic stroke ...
Masahiro Yasaka
doaj   +1 more source

Calcific uraemic arteriolopathy - A mini-review [PDF]

, 2016
Calcific Uraemic Arteriolopathy (CUA) or calciphylaxis, is a thrombotic disorder of skin and subcutaneous tissue which typically presents with painful purpuric nodules that may progress to necrotic ulcers, and is a severe, life-threatening condition. CUA
Agapii, Rodica, Fragoso, Andr?, Jerónimo, Teresa, Mendes, Filipa, Neves, Pedro L, Pimentel, Ana, Rocha, Sofia Couto, Silva, Ana   +7 more
core  

Moxifloxacin-warfarin interaction [PDF]

Journal of Community Hospital Internal Medicine Perspectives, 2012
Two case reports presented here show elevated prothrombin time/international normalized ratios (PT/INR) following coadministration of warfarin and moxifloxacin. Although the underlying mechanism of this interaction still remains unclear, health care providers should be careful when prescribing moxifloxacin to patients on warfarin therapy, especially to
Yan Ji, Youssef Hokayem
openaire   +4 more sources

Quantitative Model‐Informed Dose Selection for a Milvexian Phase III Study in Patients With Atrial Fibrillation

Clinical Pharmacology &Therapeutics, EarlyView.
Milvexian, an activated factor XI inhibitor, is being evaluated in the LIBREXIA phase III program for the prevention of thrombotic events, including in patients with atrial fibrillation (LIBREXIA AF). To guide the selection of a phase III dose regimen for LIBREXIA AF, two main approaches were used: (1) population pharmacokinetics and exposure–response ...
Wangda Zhou, Emily Bozenhardt, Gregory E. Alexander, Matthew L. Zierhut, Samira Merali, Antoinette Ajavon‐Hartmann, Peter Zannikos, Hyunmoon Back, EunYoung Suh, Navin Goyal, Mahesh N. Samtani, Alexei N. Plotnikov, Chandni Valiathan   +12 more
wiley   +1 more source